Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5061
Abstract: Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. read more here.
Keywords: dosing patterns; melanoma; nivolumab dosing; world nivolumab ... See more keywords